APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pegfilgrastim Biosimilar

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pegfilgrastim Biosimilar Industry Growth and Trends Forecast to 2032

19 December 202591 pages

Choose your research edition.

Industry ResearchPegfilgrastim Biosimilar Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Pegfilgrastim Biosimilar Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Pegfilgrastim Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pegfilgrastim Biosimilar Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Pegfilgrastim Biosimilar Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pegfilgrastim Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pegfilgrastim Biosimilar include Biocon, Coherus BioSciences, Dr Reddy’s Laboratories, Intas Pharmaceuticals, Mundipharma International, Pfizer, Mylan and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pegfilgrastim Biosimilar market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pegfilgrastim Biosimilar market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pegfilgrastim Biosimilar market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pegfilgrastim Biosimilar.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pegfilgrastim Biosimilar market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pegfilgrastim Biosimilar Market by Company

Biocon

Coherus BioSciences

Dr Reddy’s Laboratories

Intas Pharmaceuticals

Mundipharma International

Pfizer

Mylan

Novartis

Pegfilgrastim Biosimilar Segment by Type

Chemotherapy Treatment

Transplantation

Pegfilgrastim Biosimilar Segment by Application

Mail-Order Pharmacies

Hospital Pharmacies

Retail Pharmacies

Pegfilgrastim Biosimilar Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pegfilgrastim Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pegfilgrastim Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pegfilgrastim Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pegfilgrastim Biosimilar manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pegfilgrastim Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Chemotherapy Treatment Table 2. Major Company of Transplantation Table 3. Global Pegfilgrastim Biosimilar Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units) Table 5. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Type (2021-2026) Table 6. Global Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 7. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Type (2021-2026) Table 8. Global Pegfilgrastim Biosimilar Price by Type (2021-2026) & (US$/Unit) Table 9. Global Pegfilgrastim Biosimilar Sales by Type (2027-2032) & (K Units) Table 10. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Type (2027-2032) Table 11. Global Pegfilgrastim Biosimilar Sales by Type (2027-2032) & (US$ Million) Table 12. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Type (2027-2032) Table 13. Global Pegfilgrastim Biosimilar Price by Type (2027-2032) & (US$/Unit) Table 14. North America Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units) Table 15. North America Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units) Table 17. Europe Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units) Table 21. Latin America Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Pegfilgrastim Biosimilar Sales by Type (2021-2026) & (US$ Million) Table 24. Pegfilgrastim Biosimilar Industry Trends Table 25. Pegfilgrastim Biosimilar Industry Drivers Table 26. Pegfilgrastim Biosimilar Industry Opportunities and Challenges Table 27. Pegfilgrastim Biosimilar Industry Restraints Table 28. Global Pegfilgrastim Biosimilar Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Pegfilgrastim Biosimilar Revenue Market Share by Company (2021-2026) Table 30. Global Pegfilgrastim Biosimilar Sales by Company (2021-2026) & (K Units) Table 31. Global Pegfilgrastim Biosimilar Sales Share by Company (2021-2026) Table 32. Global Pegfilgrastim Biosimilar Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Pegfilgrastim Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Pegfilgrastim Biosimilar Major Company Production Sites and Headquarters Table 35. Global Pegfilgrastim Biosimilar Company, Product Type & Application Table 36. Global Pegfilgrastim Biosimilar Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Pegfilgrastim Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Pegfilgrastim Biosimilar Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Pegfilgrastim Biosimilar Sales by Region (2021-2026) & (K Units) Table 41. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Region (2021-2026) Table 42. Global Pegfilgrastim Biosimilar Sales by Region (2021-2026) & (US$ Million) Table 43. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Region (2021-2026) Table 44. Global Pegfilgrastim Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Pegfilgrastim Biosimilar Sales by Region (2027-2032) & (K Units) Table 46. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Region (2027-2032) Table 47. Global Pegfilgrastim Biosimilar Sales by Region (2027-2032) & (US$ Million) Table 48. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Region (2027-2032) Table 49. Global Pegfilgrastim Biosimilar Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Pegfilgrastim Biosimilar Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units) Table 52. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Application (2021-2026) Table 53. Global Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 54. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Application (2021-2026) Table 55. Global Pegfilgrastim Biosimilar Price by Application (2021-2026) & (US$/Unit) Table 56. Global Pegfilgrastim Biosimilar Sales by Application (2027-2032) & (K Units) Table 57. Global Pegfilgrastim Biosimilar Sales Market Share in Volume by Application (2027-2032) Table 58. Global Pegfilgrastim Biosimilar Sales by Application (2027-2032) & (US$ Million) Table 59. Global Pegfilgrastim Biosimilar Sales Market Share in Value by Application (2027-2032) Table 60. Global Pegfilgrastim Biosimilar Price by Application (2027-2032) & (US$/Unit) Table 61. North America Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units) Table 62. North America Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units) Table 64. Europe Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units) Table 68. Latin America Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Pegfilgrastim Biosimilar Sales by Application (2021-2026) & (US$ Million) Table 71. Biocon Company Information Table 72. Biocon Business Overview Table 73. Biocon Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Biocon Pegfilgrastim Biosimilar Product Portfolio Table 75. Biocon Recent Development Table 76. Coherus BioSciences Company Information Table 77. Coherus BioSciences Business Overview Table 78. Coherus BioSciences Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolio Table 80. Coherus BioSciences Recent Development Table 81. Dr Reddy’s Laboratories Company Information Table 82. Dr Reddy’s Laboratories Business Overview Table 83. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolio Table 85. Dr Reddy’s Laboratories Recent Development Table 86. Intas Pharmaceuticals Company Information Table 87. Intas Pharmaceuticals Business Overview Table 88. Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolio Table 90. Intas Pharmaceuticals Recent Development Table 91. Mundipharma International Company Information Table 92. Mundipharma International Business Overview Table 93. Mundipharma International Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Mundipharma International Pegfilgrastim Biosimilar Product Portfolio Table 95. Mundipharma International Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Pegfilgrastim Biosimilar Product Portfolio Table 100. Pfizer Recent Development Table 101. Mylan Company Information Table 102. Mylan Business Overview Table 103. Mylan Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Mylan Pegfilgrastim Biosimilar Product Portfolio Table 105. Mylan Recent Development Table 106. Novartis Company Information Table 107. Novartis Business Overview Table 108. Novartis Pegfilgrastim Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Novartis Pegfilgrastim Biosimilar Product Portfolio Table 110. Novartis Recent Development Table 111. North America Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. North America Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units) Table 113. North America Pegfilgrastim Biosimilar Sales Market Share by Country (2021-2026) Table 114. North America Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032) & (K Units) Table 115. North America Pegfilgrastim Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 116. North America Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. North America Pegfilgrastim Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 118. North America Pegfilgrastim Biosimilar Market Share by Country (2021-2026) Table 119. North America Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. North America Pegfilgrastim Biosimilar Market Share Forecast by Country (2027-2032) Table 121. Europe Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Europe Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units) Table 123. Europe Pegfilgrastim Biosimilar Sales Market Share by Country (2021-2026) Table 124. Europe Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032) & (K Units) Table 125. Europe Pegfilgrastim Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 126. Europe Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Europe Pegfilgrastim Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 128. Europe Pegfilgrastim Biosimilar Market Share by Country (2021-2026) Table 129. Europe Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Europe Pegfilgrastim Biosimilar Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units) Table 133. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share by Country (2021-2026) Table 134. Asia-Pacific Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032) & (K Units) Table 135. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Pegfilgrastim Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 138. Asia-Pacific Pegfilgrastim Biosimilar Market Share by Country (2021-2026) Table 139. Asia-Pacific Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Asia-Pacific Pegfilgrastim Biosimilar Market Share Forecast by Country (2027-2032) Table 141. Latin America Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Latin America Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units) Table 143. Latin America Pegfilgrastim Biosimilar Sales Market Share by Country (2021-2026) Table 144. Latin America Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032) & (K Units) Table 145. Latin America Pegfilgrastim Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 146. Latin America Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Latin America Pegfilgrastim Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 148. Latin America Pegfilgrastim Biosimilar Market Share by Country (2021-2026) Table 149. Latin America Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Latin America Pegfilgrastim Biosimilar Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (2021-2026) & (K Units) Table 153. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share by Country (2021-2026) Table 154. Middle East and Africa Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032) & (K Units) Table 155. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Pegfilgrastim Biosimilar Market Size by Country (2021-2026) & (US$ Million) Table 158. Middle East and Africa Pegfilgrastim Biosimilar Market Share by Country (2021-2026) Table 159. Middle East and Africa Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Middle East and Africa Pegfilgrastim Biosimilar Market Share Forecast by Country (2027-2032) Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Pegfilgrastim Biosimilar Distributors List Table 164. Pegfilgrastim Biosimilar Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Pegfilgrastim Biosimilar Image Figure 2. Global Pegfilgrastim Biosimilar Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pegfilgrastim Biosimilar Market Size (2021-2032) & (US$ Million) Figure 4. Global Pegfilgrastim Biosimilar Sales (2021-2032) & (K Units) Figure 5. Chemotherapy Treatment Image Figure 6. Global Chemotherapy Treatment Sales YoY Growth (2021-2032) & (K Units) Figure 7. Transplantation Image Figure 8. Global Transplantation Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Pegfilgrastim Biosimilar Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Pegfilgrastim Biosimilar Market Share by Type 2025 VS 2032 Figure 11. North America Pegfilgrastim Biosimilar Sales Market Share in Volume by Type in 2025 Figure 12. North America Pegfilgrastim Biosimilar Sales Market Share in Value by Type in 2025 Figure 13. Europe Pegfilgrastim Biosimilar Sales Market Share in Volume by Type in 2025 Figure 14. Europe Pegfilgrastim Biosimilar Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share in Value by Type in 2025 Figure 17. Latin America Pegfilgrastim Biosimilar Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Pegfilgrastim Biosimilar Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Pegfilgrastim Biosimilar Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Mail-Order Pharmacies Image Figure 24. Global Mail-Order Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 25. Hospital Pharmacies Image Figure 26. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 27. Retail Pharmacies Image Figure 28. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Pegfilgrastim Biosimilar Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Pegfilgrastim Biosimilar Market Share by Application 2025 VS 2032 Figure 31. North America Pegfilgrastim Biosimilar Sales Market Share in Volume by Application in 2025 Figure 32. North America Pegfilgrastim Biosimilar Sales Market Share in Value by Application in 2025 Figure 33. Europe Pegfilgrastim Biosimilar Sales Market Share in Volume by Application in 2025 Figure 34. Europe Pegfilgrastim Biosimilar Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Pegfilgrastim Biosimilar Sales Market Share in Value by Application in 2025 Figure 37. Latin America Pegfilgrastim Biosimilar Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Pegfilgrastim Biosimilar Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Pegfilgrastim Biosimilar Sales Market Share in Value by Application in 2025 Figure 41. North America Pegfilgrastim Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Pegfilgrastim Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Pegfilgrastim Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Pegfilgrastim Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Pegfilgrastim Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Pegfilgrastim Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Pegfilgrastim Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Pegfilgrastim Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Pegfilgrastim Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Pegfilgrastim Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Pegfilgrastim Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Pegfilgrastim Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Pegfilgrastim Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Pegfilgrastim Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Pegfilgrastim Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Pegfilgrastim Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Pegfilgrastim Biosimilar Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Pegfilgrastim Biosimilar Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Pegfilgrastim Biosimilar Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Pegfilgrastim Biosimilar Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Pegfilgrastim Biosimilar Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Pegfilgrastim Biosimilar Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Chemotherapy Treatment
  • Transplantation
Applications
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Biocon
  • Coherus BioSciences
  • Dr Reddy’s Laboratories
  • Intas Pharmaceuticals
  • Mundipharma International
  • Pfizer
  • Mylan
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pegfilgrastim Biosimilar Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pegfilgrastim Biosimilar Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pegfilgrastim Biosimilar Market by Type
  6. 1.3.1 Chemotherapy Treatment
  7. 1.3.2 Transplantation
  8. 1.4 Global Pegfilgrastim Biosimilar Market Size by Type
  9. 1.4.1 Global Pegfilgrastim Biosimilar Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Pegfilgrastim Biosimilar Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Pegfilgrastim Biosimilar Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Pegfilgrastim Biosimilar Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Pegfilgrastim Biosimilar Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Pegfilgrastim Biosimilar Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Pegfilgrastim Biosimilar Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Pegfilgrastim Biosimilar Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pegfilgrastim Biosimilar Industry Trends
  2. 2.2 Pegfilgrastim Biosimilar Industry Drivers
  3. 2.3 Pegfilgrastim Biosimilar Industry Opportunities and Challenges
  4. 2.4 Pegfilgrastim Biosimilar Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pegfilgrastim Biosimilar Revenue (2021-2026)
  2. 3.2 Global Top Players by Pegfilgrastim Biosimilar Sales (2021-2026)
  3. 3.3 Global Top Players by Pegfilgrastim Biosimilar Price (2021-2026)
  4. 3.4 Global Pegfilgrastim Biosimilar Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pegfilgrastim Biosimilar Major Company Production Sites & Headquarters
  6. 3.6 Global Pegfilgrastim Biosimilar Company, Product Type & Application
  7. 3.7 Global Pegfilgrastim Biosimilar Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pegfilgrastim Biosimilar Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pegfilgrastim Biosimilar Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pegfilgrastim Biosimilar Tier 1, Tier 2, and Tier 3
4 Pegfilgrastim Biosimilar Regional Status and Outlook
  1. 4.1 Global Pegfilgrastim Biosimilar Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pegfilgrastim Biosimilar Historic Market Size by Region
  3. 4.2.1 Global Pegfilgrastim Biosimilar Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pegfilgrastim Biosimilar Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pegfilgrastim Biosimilar Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pegfilgrastim Biosimilar Forecasted Market Size by Region
  7. 4.3.1 Global Pegfilgrastim Biosimilar Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pegfilgrastim Biosimilar Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pegfilgrastim Biosimilar Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pegfilgrastim Biosimilar by Application
  1. 5.1 Pegfilgrastim Biosimilar Market by Application
  2. 5.1.1 Mail-Order Pharmacies
  3. 5.1.2 Hospital Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Pegfilgrastim Biosimilar Market Size by Application
  6. 5.2.1 Global Pegfilgrastim Biosimilar Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Pegfilgrastim Biosimilar Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Pegfilgrastim Biosimilar Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Pegfilgrastim Biosimilar Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Pegfilgrastim Biosimilar Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Pegfilgrastim Biosimilar Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Pegfilgrastim Biosimilar Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Pegfilgrastim Biosimilar Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biocon
  2. 6.1.1 Biocon Company Information
  3. 6.1.2 Biocon Business Overview
  4. 6.1.3 Biocon Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biocon Pegfilgrastim Biosimilar Product Portfolio
  6. 6.1.5 Biocon Recent Developments
  7. 6.2 Coherus BioSciences
  8. 6.2.1 Coherus BioSciences Company Information
  9. 6.2.2 Coherus BioSciences Business Overview
  10. 6.2.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolio
  12. 6.2.5 Coherus BioSciences Recent Developments
  13. 6.3 Dr Reddy’s Laboratories
  14. 6.3.1 Dr Reddy’s Laboratories Company Information
  15. 6.3.2 Dr Reddy’s Laboratories Business Overview
  16. 6.3.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolio
  18. 6.3.5 Dr Reddy’s Laboratories Recent Developments
  19. 6.4 Intas Pharmaceuticals
  20. 6.4.1 Intas Pharmaceuticals Company Information
  21. 6.4.2 Intas Pharmaceuticals Business Overview
  22. 6.4.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolio
  24. 6.4.5 Intas Pharmaceuticals Recent Developments
  25. 6.5 Mundipharma International
  26. 6.5.1 Mundipharma International Company Information
  27. 6.5.2 Mundipharma International Business Overview
  28. 6.5.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Mundipharma International Pegfilgrastim Biosimilar Product Portfolio
  30. 6.5.5 Mundipharma International Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Pegfilgrastim Biosimilar Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Mylan
  38. 6.7.1 Mylan Company Information
  39. 6.7.2 Mylan Business Overview
  40. 6.7.3 Mylan Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Mylan Pegfilgrastim Biosimilar Product Portfolio
  42. 6.7.5 Mylan Recent Developments
  43. 6.8 Novartis
  44. 6.8.1 Novartis Company Information
  45. 6.8.2 Novartis Business Overview
  46. 6.8.3 Novartis Pegfilgrastim Biosimilar Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Novartis Pegfilgrastim Biosimilar Product Portfolio
  48. 6.8.5 Novartis Recent Developments
7 North America by Country
  1. 7.1 North America Pegfilgrastim Biosimilar Sales by Country
  2. 7.1.1 North America Pegfilgrastim Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pegfilgrastim Biosimilar Sales by Country (2021-2026)
  4. 7.1.3 North America Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pegfilgrastim Biosimilar Market Size by Country
  6. 7.2.1 North America Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pegfilgrastim Biosimilar Market Size by Country (2021-2026)
  8. 7.2.3 North America Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pegfilgrastim Biosimilar Sales by Country
  2. 8.1.1 Europe Pegfilgrastim Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pegfilgrastim Biosimilar Sales by Country (2021-2026)
  4. 8.1.3 Europe Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pegfilgrastim Biosimilar Market Size by Country
  6. 8.2.1 Europe Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pegfilgrastim Biosimilar Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pegfilgrastim Biosimilar Sales by Country
  2. 9.1.1 Asia-Pacific Pegfilgrastim Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pegfilgrastim Biosimilar Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pegfilgrastim Biosimilar Market Size by Country
  6. 9.2.1 Asia-Pacific Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pegfilgrastim Biosimilar Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pegfilgrastim Biosimilar Sales by Country
  2. 10.1.1 South America Pegfilgrastim Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pegfilgrastim Biosimilar Sales by Country (2021-2026)
  4. 10.1.3 South America Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pegfilgrastim Biosimilar Market Size by Country
  6. 10.2.1 South America Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pegfilgrastim Biosimilar Market Size by Country (2021-2026)
  8. 10.2.3 South America Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pegfilgrastim Biosimilar Sales by Country
  2. 11.1.1 Middle East and Africa Pegfilgrastim Biosimilar Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pegfilgrastim Biosimilar Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pegfilgrastim Biosimilar Market Size by Country
  6. 11.2.1 Middle East and Africa Pegfilgrastim Biosimilar Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pegfilgrastim Biosimilar Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pegfilgrastim Biosimilar Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pegfilgrastim Biosimilar Value Chain Analysis
  2. 12.1.1 Pegfilgrastim Biosimilar Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pegfilgrastim Biosimilar Production Mode & Process
  7. 12.2 Pegfilgrastim Biosimilar Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pegfilgrastim Biosimilar Distributors
  10. 12.2.3 Pegfilgrastim Biosimilar Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst